Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin

Journal of Clinical Pharmacology

Volumn 40, Issue 5, 2000, Pages 488-495

  Reimann, James D ^a   Modi, Nishit B ^a,b   Novotny, William ^a  

^a GENENTECH INC   (United States)

^b ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; SIBRAFIBAN;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; ASPIRIN; BLEEDING TIME; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; OXIMES; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRODRUGS; PROTHROMBIN TIME; RECEPTORS, THROMBIN;

EID: 0033669093     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009107     Document Type: Article

References (16)

1. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial
2. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally-administered IIb/IIIa antagonist, in patients with acute coronary syndrome
3. Pharmacokinetics and pharmacodynamics of Ro 44-3666 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers
4. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form
5. Orally active fibrinogen receptor antagonists: 2. Amidoximes as prodrugs of amidines
6. Antiplatelet therapy with aspirin: From clinical trials to practice
7. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
8. 2 and prostacyclin
9. The standardized normal Ivy bleeding time and its prolongation by aspirin
10. On the mechanism of platelet aggregation induced by heparin, protamine and polybrene
11. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo
12. Effect of heparin and heparin fractions on platelet aggregation
13. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
14. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor agonist, in healthy men
15. Inhibition and reversal of platelet aggregation by methyl xanthines
16. Aspirin as an antiplatelet drug